The Slovak Medical University in Bratislava - SMU is a state "college of university type" seated in Bratislava, Slovakia. It was created by law from 25 June 2002 with effect from 1 September 2002 and replaced the Slovak Postgraduate Academy of Medicine .The Slovak Medical University in Bratislava is an educational institution proudly keeping the tradition of education of healthcare workers in specialized studies and continuous lifelong education in Slovakia.The Slovak Institute for Postgraduate Education of Physicians, established on May 1, 1953 in Trenčín, laid the foundations of education of healthcare professionals in Slovakia. From July 7, 1966, the Institute moved into new premises in Bratislava, under a new name – The Institute of Further Education of Physicians and Pharmacists, which remained until 1991. On July 1, 1991, the name was changed to the Institute for Further Education of Professionals in Healthcare, and later, resulting from requirements in practice, the last change on November 1, 1998 transformed it into the Slovak Postgraduate Academy of Medicine in Bratislava.On September 1, 2002, the Slovak Medical University was founded in Bratislava by Act No. 401/2002 Coll. of the National Council of the Slovak Republic on the establishment of the Slovak Medical University, as a state university of higher education.The Slovak Medical University in Bratislava is the only university in Slovakia that provides monothematic education for healthcare professions in all three degrees of higher education, and at the same time, the only institution that has guaranteed complex education of healthcare workers in Slovakia under various names since 1953. Wikipedia.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: KBBE.2013.3.5-03 | Award Amount: 3.77M | Year: 2014
G-TwYST will execute rat feeding trials with GM maize NK 603 based on OECD Test Guidelines and according to EFSA considerations. In the case of maize NK603 two 90-day and a combined 2-year chronic toxicity/carcinogenicity study will be performed. By combining the results of the G-TwYST project with those of the GRACE project (90-day and 1-year study with maize MON810) it will be possible for the first time to describe the potential medium term and long term toxic effects of the two above-mentioned events. Partners will strictly comply with international standards and norms concerning feeding trials and closely collaborate with EFSA. Feeding stuff used in the trials will be produced according to the principles of good agricultural practice. The project will analyse and report the results of the feeding trials and develop recommendations on the scientific justification and added value of long-term feeding trials for GMO risk assessment. The project will ensure scientific excellence, independence and transparency of both the research process and the results. Transparency and accessibility of project plans and results is a key characteristic of the project and will be ensured by establishing a project website and by using an open access database set up by GRACE as information hubs. Results will be published as open access journal papers. Dedicated engagement, communication, and dissemination activities will target scientists, policy makers and a broad range of stakeholders. Participatory steps will be included in the planning as well as in the interpretation/conclusion phase. Moreover, the views of risk assessment and regulatory bodies as well as wider societal issues will also be taken into consideration. The results of the project will enable risk managers drawing conclusions with regard to framework of the currently applicable GM food/feed risk assessment requirements and procedures in the EU.
Szatmary Z.,Slovak Medical University
General Physiology and Biophysics | Year: 2012
Toll-like receptors (TLRs) play important roles in host resistance to infections, but also act as mediators of pathologies in autoimmunity, septic shock, metabolic disease and cancer. TLRs are expressed in sentinel cells of the immune system (most notably dendritic cells and macrophages) and are key sensors of bacteria, viruses, fungi and protozoa (O'Neill 2006). TLRs also recognize endogenous ligands present in tissues and cells in the absence of infection (Kawai and Akira 2005; Nizet 2006; Kim et al. 2009). In this review, the TLRs are characterized at the cellular level with emphasis on TLR-mediated signaling pathways along with their negative regulation, including specificity of the response(s) at the promoter level.
Agency: Cordis | Branch: FP7 | Program: CP-CSA-Infra | Phase: INFRA-2010-1.1.31 | Award Amount: 8.95M | Year: 2011
Nanoscale objects interact with living organisms in a fundamentally new manner, ensuring that a fruitful marriage of nanotechnology and biology will long outlast short term imperatives. Therefore, investment in an infrastructure to drive scientific knowledge of the highest quality will have both immediate benefits of supporting the safety assessment of legacy nanomaterials, as well as pointing towards future (safe) applications with the lasting benefits to society. There are immediate priorities, for few doubt that serious damage to confidence in nanotechnology, unless averted, could result in missed opportunities to benefit society for a generation, or more. QNano will materially affect the outcome, at this pivotal moment of nanotechnology implementation. The overall vision of QNano is the creation of a neutral scientific & technical space in which all stakeholder groups can engage, develop, and share scientific best practice in the field. Initially it will harness resources from across Europe and develop efficient, transparent and effective processes. Thereby it will enable provision of services to its Users, and the broader community, all in the context of a best-practice ethos. This will encourage evidence-based dialogue to prosper between all stakeholders. However, QNano will also pro-actively seek to drive, develop and promote the highest quality research and practices via its JRA, NA and TA functions, with a global perspective and mode of implementation. QNano will also look to the future, beyond the current issues, and promote the growth and development of the science of nanoscale interactions with living organisms. By working with new and emerging scientific research communities from medicine, biology, energy, materials and others, it will seek to forge new directions leading to new (safe, responsible, economically viable) technologies for the benefit of European society.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: KBBE.2012.3.5-04 | Award Amount: 7.76M | Year: 2012
The project GRACE will a) elaborate and sustainably implement a transparent framework for the review of GMOs or GM food and feed effects on environment, socio-economics and health and b) reconsider the design, execution and interpretation of results of animal feeding trials as well as in vitro studies for assessing the safety of GM food and feed. The framework will create high quality reviewing processes for different fields of GMO impact assessment and address the need for a well documented, transparent and sustainable representation of these reviewing processes. This will provide valuable and accessible information addressing the main issues associated with GMOs and enabling risk assessors, managers, scientists and the general public to reiterate and update their evaluations and conclusions on GMOs. It will adapt recently elaborated methodologies for (systematic) reviewing of the risk assessment information of GMOs and derived food and feed. The quality assessment for all reviewed papers and studies as well as the reviews conducted by the consortium, will be referenced by an open access database and one-stop-shop for data and information relevant to GMO risk assessment. Animal feeding trials and in vitro studies will clarify and compare the scientific added value of 90day feeding trials with whole foods with advanced state-of-the-art analytical, in vitro and in-silico tools. Suitable animal GMO-feeding models will be investigated, that are based on European (EFSA) and international guidance, and the project will provide guidance for relevant, alternative in vitro cell-based approaches for specific topics within the overall food and feed safety assessment. Available standard or scientifically approved protocols form the basis of the investigations also in the case of the analytical, in-vitro and second in-silico approaches. GRACE will provide guidance for the use and improvement of existing and suggested assessment tools in the field of food and feed safety.
Agency: Cordis | Branch: H2020 | Program: ERC-COG | Phase: ERC-CoG-2014 | Award Amount: 1.95M | Year: 2015
Viral infection or retrotransposon expansion in the genome often result in production of double-stranded RNA (dsRNA). dsRNA can be intercepted by RNase III Dicer acting in the RNA interference (RNAi) pathway, an ancient eukaryotic defense mechanism. Notably, endogenous mammalian RNAi appears dormant while its common and unique physiological roles remain poorly understood. A factor underlying mammalian RNAi dormancy is inefficient processing of dsRNA by the full-length Dicer. Yet, a simple truncation of Dicer leads to hyperactive RNAi, which is naturally present in mouse oocytes. The D-FENS project will use genetic animal models to define common, cell-specific and species-specific roles of mammalian RNAi. D-FENS has three complementary and synergizing objectives: (1) Explore consequences of hyperactive RNAi in vivo. A mouse expressing a truncated Dicer will reveal at the organismal level any negative effect of hyperactive RNAi, the relationship between RNAi and mammalian immune system, and potential of RNAi to suppress viral infections in mammals. (2) Define common and species-specific features of RNAi in the oocyte. Functional and bioinformatics analyses in mouse, bovine, and hamster oocytes will define rules and exceptions concerning endogenous RNAi roles, including RNAi contribution to maternal mRNA degradation and co-existence with the miRNA pathway. (3) Uncover relationship between RNAi and piRNA pathways in suppression of retrotransposons. We hypothesize that hyperactive RNAi in mouse oocytes functionally complements the piRNA pathway, a Dicer-independent pathway suppressing retrotransposons in the germline. Using genetic models, we will explore unique and redundant roles of both pathways in the germline. D-FENS will uncover physiological significance of the N-terminal part of Dicer, fundamentally improve understanding RNAi function in the germline, and provide a critical in vivo assessment of antiviral activity of RNAi with implications for human therapy.